[PSA] TRIUMPH is not what most of this community thinks it is
Short public-service post: TRIUMPH is not what most of this community thinks it is.
Went up slowly, deliberately, because everything on this board says the escalation is where trouble lives. Uneventful so far and I am not going to pretend that is a finding.
Phase 2 estimates effect and finds a dose range. Phase 3 estimates it precisely in a bigger population and catches what phase 2 was too small to see. Treating them as the same tier of evidence is the recurring error here.
Nothing containing this compound is approved anywhere. Research-use-only material is not approved for human use, and that is a statement of fact rather than a disclaimer.
I will update this if the picture changes rather than quietly leaving it up.
best — the order this archive was captured in
The phase 2 readout ran to 48 weeks in a few hundred participants with a slow escalation. Both the size and the duration matter when people quote the headline number.
wait for phase 3 before you argue about rankings
Increases in heart rate have been reported across this receptor class. The magnitude and clinical significance are exactly what phase 3 is powered to establish.
How fast was the escalation? That is usually the variable that explains the reports.
That reads as a titration plan for an unapproved compound. This board cannot host that and it should not want to.
triple agonist — GLP-1, GIP and glucagon, and the glucagon arm is the new part
a lot of the confident posting here is extrapolation
[removed by moderator]
That is body weight change, not fat mass. The trials report the first and people quote it as the second.
the glucagon component is why the metabolic story reads differently
research-use-only material is not approved for human use, full stop
Disagree. "More receptors means more effect" is not how any of this works and the trial data does not support the linear story.